Marta Wosinska

Jul 5, 2024 | brookings.edu | Marta Wosinska |Richard Frank

Marta Wosińska and Richard Frank recently commented on a Senate Finance Committee legislative draft proposing a Medicare Drug Shortage Prevention and Mitigation Program (“Shortage Program”) and an exemption from Medicaid inflation rebates for multisource generics.

Mar 13, 2024 | brookings.edu | Marta Wosinska

High-profile shortages of amoxicillin, cancer drugs, and medications to treat attention deficit hyperactive disorder (ADHD) have put drug shortages in the headlines over the past year. Less visible but equally alarming have been shortages of lifesaving emergency drugs such as atropine and epinephrine. Many of these shortages are persistent. These shortages throw into question the reliability of the U.S. drug supply chain.

Jan 11, 2024 | brookings.edu | Marta Wosinska |Rena Conti |Elisabeth B. Reynolds

On March 2, 2023, the authors convened a group of experts from academia, industry, government, and nonprofits to explore technology options for increasing the resilience in the supply of generic prescription drugs. The workshop was convened at the Massachusetts Institute of Technology with the help of the National Network for Critical Technology Assessment and financial support from the Alfred P. Sloan Foundation. This report, authored by the organizers, summarizes the discussion.

Dec 5, 2023 | brookings.edu | Marta Wosinska

Editor's note: The following testimony was given to the Senate Committee on Finance on December 5, 2023. The original version of the submitted testimony and a video of the hearing is available here. The version below was edited for clarity and accuracy. Chairman Wyden, Ranking Member Crapo, and members of the Committee, thank you for inviting me here today.

Nov 1, 2023 | brookings.edu | Marta Wosinska |Rena Conti

In October 2023, Marta Wosińska and Rena Conti concluded a one-year pilot demonstration of how analytics can inform national technology strategy in biopharmaceuticals. Their demonstration was part of a large, cross-industry pilot titled the National Network for Critical Technology Assessment.